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ABSTRACT 
Objective: To develop and validate a new simple, accurate, precise and sensitive high performance liquid chromatographic method (HPLC) method for 
simultaneous estimation of ubidecarenone and vitamin E acetate in capsule dosage form as per international conference on harmonization (ICH) guidelines.  
Methods: The chromatographic separation of drugs were achieved using hypersil C8
Results: The optimized method produced sharp peaks with good resolution, minimum tailing factor and satisfactory retention time were found to 
be 5.745 min and 12.565 min for vitamin E acetate and ubidecarenone respectively. The method was linear in the range of 60-180 µg/ml for 
ubidecarenone and 20-60 µg/ml for vitamin E acetate with a correlation coefficient of 0.999 and 0.9993 respectively. Mean recoveries observed for 
ubidecarenone and vitamin E acetate were 99.85% and 99.73% respectively. The percentage relative standard deviation (% RSD) of peak area for 
system precision, method precision, and intermediate precision were found to be less than 0.37%. The lower degree of % RSD obtained has proved 
that the method was precise and robust.  
 column (250 mm x 4.6 mm, 5µ) in isocratic elution mode with 
a mobile phase of methanol: ethanol: n-hexane (80:10:10 v/v/v) at a flow rate of 1 ml/min with ultra-violet (UV) detection at 210 nm. 
Conclusion: A new simple HPLC method was developed and validated as per ICH guidelines for the simultaneous estimation of ubidecarenone and 
vitamin E acetate and the method can be effectively applied for the routine analysis of active pharmaceutical ingredient (API) and formulations. 
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Ubidecarenone is chemically 2-[(all-E)-3,7,11,15,19,23,27,31,35,39-
Decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl]-5,6-
dimethoxy-3-methylbenzene-1,4-dione, which is also called as coenzyme 
Q10 [1]. It is a lipid-soluble compound found naturally in plants, animals 
and in microorganisms [2]. It is a biologically active compound, 
characterized by a quinone ring attached to a repeating series of side 
chain isoprene units (fig. 1). It is an excellent anti-oxidant in the reduced 
state [3]. It is used as a dietary supplement and cardiovascular agent in 
congestive heart failure and in angina pectoris [4, 5].  
Alpha-tocopherol is the most active form of vitamin E in humans. It is a 
powerful biological antioxidant play a fundamental part in the 
functioning of the human body [6]. Vitamin E in supplements is usually 
sold as vitamin E acetate (alpha-tocopheryl acetate). The synthetic 
form is labeled as DL-alpha-tocopheryl acetate (fig. 2), chemically 
known as All-rac-2, 5, 7, 8-tetramethyl-2-(4, 8, 12-trimethyltridecyl)-
3,4-dihydro-2H-1-benzopyran-6-yl acetate [7, 8]. Vitamin E has a 
strong anti-oxidant character, influences the activity of the nervous 
system and high level of supplementary alpha-tocopherol reduces 
mortality caused by cardiovascular diseases. Vitamin E was reported 
to be effective in reducing atherosclerosis progression in subjects with 
previous coronary artery bypass graft surgery not treated with lipid-
lowering drugs [9].  
 
 
Fig. 1: Chemical structure of ubidecarenone 
 
Fig. 2: Chemical structure of vitamin E acetate 
 
The literature survey revealed that few UV spectrophotometric 
methods [1, 10, 11], HPLC [12-18] and bio-analytical [19, 20] 
methods were reported for the estimation of ubidecarenone alone or 
in combination with other drugs. And also several methods like 
HPLC [21-26], UV [27, 28] were described for vitamin E acetate 
alone or in combination with other drugs. But no method has been 
reported for the estimation of ubidecarenone and vitamin E acetate 
in the capsule dosage form. Hence the main objective of the 
proposed method was to develop and validate a simple, accurate and 
sensitive HPLC method for the simultaneous determination of 
ubidecarenone and vitamin E acetate in the capsule dosage form. 
MATERIALS AND METHODS 
Chemicals and reagents 
Ubidecarenone and vitamin E acetate reference standards were 
obtained as gift sample from Sai Mirra Innopharm pvt ltd, Chennai 
and Surien pharmaceuticals, Chennai respectively. Zen Q10 capsule 
(Minova life sciences pvt ltd., Bangalore) was procured from the 
local market. Label claim of Zen Q10 capsule for ubidecarenone and 
vitamin E acetate is 100 mg and 200 mg respectively. Methanol, 
ethanol, and n-hexane (HPLC grade) were purchased from E. Merck 
India ltd., Mumbai. 
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Instrumentation and chromatographic conditions 
A shimadzu HPLC instrument–LC 20AD with UV-VIS SPD-20A detector 
was used. The data was recorded by using LC solution software. 
The chromatographic separation of drugs was achieved using 
hypersil C8
Specificity study was conducted to assess the interferences that may 
be caused by the presence of excipients and degradation products 
that may be expected to present in the sample. In the current work, 
specificity was demonstrated by injecting blank, placebo with 
excipients, standard solution and sample solution and the 
chromatograms were compared for interferences. 
 column (250 mm x 4.6 mm, 5µ) in isocratic elution mode 
with a mobile phase of methanol: ethanol: n-hexane (80:10:10 
v/v/v) at a flow rate of 1 ml/min with UV detection at 210 nm. 
Mobile phase preparation 
The mobile phase was prepared by mixing methanol, ethanol, and n-
hexane in the proportion of 80:10:10 v/v/v and it was degassed by 
sonication for 15 min.  
Preparation of standard solution 
60 mg of ubidecarenone and 20 mg of vitamin E acetate was 
weighed accurately and transferred into a dry 100 ml volumetric 
flask, 20 ml of diethyl ether was added and sonicated for 5 min. To 
the above solution, 30 ml of ethanol was added and again sonicated 
for 20 min. The volume was made up to 100 ml with ethanol 
(600µg/ml of ubidecarenone and 200 µg/ml of vitamin E acetate). 
From the above stock solution, 10 ml was pipetted out into a 50 ml 
volumetric flask, and the volume was made with methanol. (120 
µg/ml of ubidecarenone and 40µg/ml of vitamin E acetate).  
Preparation of sample solution 
The content of 10 capsules was mixed well, and the average content 
weight of one capsule was calculated. The average content weight of 
one capsule was weighed accurately and transferred to a dry 100 ml 
volumetric flask. To this 20 ml of diethyl ether was added and 
sonicated for 10 min and 30 ml of ethanol was added and again 
sonicated for 15 min. The above solution was filtered, and the 
volume was made up to 100 ml with ethanol. This solution contains 
1000 µg/ml of ubidecarenone and 2000 µg/ml of vitamin E acetate 
and it was appropriately diluted to get the concentration of 120 
µg/ml of ubidecarenone and 40 µg/ml of vitamin E acetate. 
Method development 
The initial chromatographic conditions were set based on the nature 
of drugs. The mobile phase composition was selected based on the 
solubility and polarity and the detection wavelength was selected 
based on the UV absorption property of the drugs. To optimize the 
method conditions trials were conducted by changing the 
chromatographic conditions initially selected to achieve satisfactory 
separation of drug peaks with proper peak shape, retention time, 
plate count, resolution and tailing factor. 
Method validation  
The developed method was validated according to ICH guidelines 
[29] for validation of analytical procedures. The method was 
validated for the parameters such as system suitability, specificity, 
precision, accuracy, linearity, robustness, and ruggedness, limit of 
detection (LOD) and limit of quantitation (LOQ).  
Specificity 
Precision 
System precision of the method was verified from six replicates of 
standard solution, and percentage relative standard deviation (% 
RSD) of peak area was calculated. Method precision was verified 
from six replicates of commercial formulation solution and % RSD of 
percentage label claim was calculated. 
Accuracy  
The recovery studies were carried out by addition of standard drug 
solution at three concentration levels, 50%, 100% and 150% to the 
previously analyzed sample solution. The above solution was 
injected in triplicate for each level, and percentage recovery of the 
known added amount was calculated.  
Linearity  
Linearity was established from 50%-150% of working concentration 
at five concentration levels in the range between 60-180 µg/ml for 
ubidecarenone and 20-60 µg/ml for vitamin E acetate. The solution of 
each concentration was injected in triplicate, and the peak area for all 
the concentration levels was measured. Linearity is evaluated by 
plotting graph with peak area in y-axis and concentration in the x-axis. 
Robustness 
Robustness was assessed by slightly changing the optimized 
chromatographic such as parameters ratio of methanol in mobile 
phase composition±5% and flow rate±0.2 ml/min. 
Ruggedness  
To verify the ruggedness of the method, the sample solution was 
analyzed in three replicates by different analysts using different 
instruments on different days. The % RSD of % mean assay was 
calculated. 
Limit of detection (LOD) and limit of quantitation (LOQ) 
LOD is defined as the lowest concentration of an analyte that an 
analytical method differentiates from background levels. The LOQ is 
defined as the lowest concentration that can be measured with 
acceptable accuracy, precision and variability. The LOD and LOQ 
were calculated from the linearity curve by using the formulae 
LOD =  
3.3 σ
S  




Where σ is the standard deviation of the y-intercept and S is the 
slope of the calibration plot [29]. 
RESULTS AND DISCUSSION 
Method development 
As a part of method development, several trials were carried out 
with various columns of different dimensions and also with different 
compositions of the mobile phase. The separation of ubidecarenone 
and vitamin E acetate was achieved using hypersil C8
  
 column (250 
mm x 4.6 mm, 5µ) in isocratic elution mode with a mobile phase of 
methanol: ethanol: n-hexane (80:10:10 v/v/v) at a flow rate of 1 
ml/min with UV detection at 210 nm. The drug peaks were 
identified by comparing the individual drug chromatogram of 
ubidecarenone and vitamin E acetate standard (fig. 3, fig. 4). 
 
Fig. 3: Ubidecarenone standard 
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Fig. 4: Vitamin E acetate standard 
 
To optimize the chromatographic conditions, the system suitability tests 
were applied to the chromatographic system to ensure the satisfactory 
performance of the method. Retention time, a number of theoretical plates 
and asymmetric peak factor was evaluated for six replicate injections of the 
standard at working concentration. The system suitability parameters 
were within the acceptance limit and are given in table 1. 
 
Table 1: System suitability parameters 
Parameters Vitamin E acetate Ubidecarenone 
Resolution  7.6 
Tailing factor 1.08 1.04 
Number of theoretical plates 10022 11191 
Retention time (min) 5.725 12.565 
Each value is average of six determinations (n=6) 
 
The applicability of the method was tested by injecting the solution 
of the commercial formulation at working concentration. The peak 
area responses were recorded, and the percentage label claim was 
calculated. The percentage label claim for ubidecarenone and 
vitamin E acetate was found to be 101.60% and 99.46% 
respectively. The assay of the drug combination in the sample is 
ranging within the acceptance limit 98-102%, which is the standard 





Fig. 5: Specificity-blank 
 
 
Fig. 6: Specificity-mixed standard 
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Fig. 7: Specificity-placebo mixed sample solution 
 
Specificity of the method was tested by comparing the response of 
blank (fig. 5), standard (fig. 6) and placebo mixed sample solution 
(fig. 7). No interference of the placebo was detected at the retention 
time of ubidecarenone and vitamin E acetate. This confirms the 
specificity of the proposed method.  
Precision 
System precision of the method was evaluated by six replicate 
injections of standard solution and the % RSD was found to be 0.36 
for ubidecarenone and 0.19 for vitamin E acetate. 
Method precision was tested by six replicate injections of 
commercial formulation solution and the % RSD of percentage label 
claim was found to be 0.37 and 0.34 respectively. For both system 
and method precision, the % RSD of response was less than 2 
indicates the method is precise. 
Accuracy 
To check the accuracy of the method, recovery studies were carried 
out by adding standard drug at three concentration levels 50%, 
100%, and 150%. At each level, three determinations were 
performed, and the percentage mean recovery was calculated. All 
observed data are within the acceptance limit of percentage 
recovery 98-102%, which indicates the accuracy of the developed 
method. The results obtained are shown in table 2. 
 
Table 2: Accuracy data (Analyte recovery study) 
% Level Amount added (µg/ml) *Amount recovered (µg/ml) *% Recovery Mean % recovery 
Ubidecarenone 50% 60 59.95±0.03  99.92±0.05 99.85 
 Ubidecarenone 100% 120 119.71±0.11  99.75±0.09 
Ubidecarenone 150% 180 179.80±0.08  99.88±0.04  
Vitamin E acetate 50% 20 19.998±0.010  99.99±0.053 99.73 
Vitamin E acetate 100% 40  39.76±0.015 99.43±0.030 
Vitamin E acetate 150% 60 59.875±0.011  99.79±0.017 
*mean±SD of three replicates (n=3) 
 
Linearity and range 
Linearity was established over the concentration level of 50% to 150% 
of the standard working concentration of ubidecarenone and vitamin 
E acetate. The five-point calibration curve obtained by plotting peak 
area versus concentration of ubidecarenone and vitamin E acetate was 
found to be linear within the concentration range from 60 to 180 
µg/ml and 20 to 60 µg/ml respectively. The linear regression was used 
for data evaluation. The linearity was expressed as a correlation 
coefficient; the value meets the acceptance criteria for both the drugs 
which are greater than 0.9993. Hence the method is said to be linear. 
The linearity results are tabulated in table 3. 
 
Table 3: Linearity data 
Parameters Ubidecarenone Vitamin E acetate 
Slope 78457 31058 
Intercept 24183 14571 
Correlation coefficient (R²) 0.999 0.9993 
Range 60-180 µg/ml 20-60 µg/ml 
 
Robustness 
The robustness of the method was demonstrated by making slight 
changes in the chromatographic conditions such as a change in the 
mobile phase composition and flow rate in the assay of sample 
preparations.  
 
The % RSD of % assay for the altered conditions was found to be less 
than 2 %. This represents the ability of the method to produce 
accurate results during the slightly distorted method conditions. The 
data is presented in table 4. 
  
Table 4: Results of robustness study 
Factor Level mean±SD of % Assay* % RSD 
Ubidecarenone Vitamin E acetate Ubidecarenone Vitamin E acetate 
Ratio of methanol in the mobile phase 75 101.59±0.67 99.58±0.08 0.66 0.09 
80 101.45±0.57 99.26±0.36 0.56 0.36 
85 102.30±0.14 100.15±1.02 0.14 1.02 
Flow rate (ml/min) 0.8 100.60±1.43 100.18±0.30 0.97 0.36 
1.0 101.45±0.57 99.26±0.36 0.56 0.30 
1.2 100.77±1.19 99.40±0.55 0.87 0.55 
*Mean of three replicates (n=3) 
Grace et al. 




The mean assay percentage of ubidecarenone and vitamin E acetate in 
sample preparation was determined as per methodology by different 
analysts on different instruments on different days, and the results are 
given in table 5. The observed value of within-laboratory variations 
showed no marked changes in the mean assay percentage of both the 
drugs, confirms the reproducibility of the proposed method. 
 
Table 5: Ruggedness data 
Parameter mean±SD of % assay* % RSD 
Ubidecarenone Vitamin E acetate Ubidecarenone Vitamin E acetate 
Day 1 101.45±0.57 99.26±0.36 0.56 0.36 
Day 2 101.61±0.15 100.24±0.39 0.15 0.39 
Analyst 1 101.45±0.57 99.26±0.36 0.57 0.36 
Analyst 2 101.59±0.09 100.06±0.77 0.09 0.77 
Instrument 1 101.45±0.57 99.26±0.36 0.57 0.36 
Instrument 2 101.53±1.24 99.49±0.60 1.12 0.66 
*Mean of three replicates (n=3) 
 
LOD and LOQ 
The LOD of ubidecarenone and vitamin E acetate was found to be 
5.06 µg/ml and 1.55 µg/ml respectively. The LOQ of ubidecarenone 
and vitamin E acetate was found to be 15.33 µg/ml and 4.71 µg/ml 
respectively. 
DISCUSSION 
Based on the literature review there is no HPLC method 
development was reported for the simultaneous estimation of 
ubidecarenone and vitamin E acetate in the capsule dosage form. The 
results of the system suitability and applicability of the method in the 
estimation of the drug combination in the marketed capsule dosage 
form confirm that the proposed method is suitable and applicable for 
routine laboratory analysis. The method validation results of the 
present study are within the specified acceptance criteria as per ICH 
guidelines [29]. The %RSD of the precision study and robustness is 
less than 2% which indicates the repeatability, reproducibility, and 
strength of the method to withstand the variation in the method 
conditions, The mean % recovery is within 98-102%, the correlation 
coefficient calculated from the linearity study is greater than 0.99 and 
the very low LOD and LOQ values prove that the intended method is 
accurate, linear and extremely sensitive. Hence this method can be 
effectively applied for the separation and determination of the drugs 
ubidecarenone and vitamin E acetate. 
CONCLUSION 
A new simple HPLC method was developed for simultaneous 
estimation of ubidecarenone and vitamin E acetate in the capsule 
dosage form. The method provides good resolution between the 
drugs with less retention time. The results of validation parameters 
have proved that the proposed method is precise, accurate, robust 
and sensitive. The sample recoveries in the formulation were in 
good agreement with their respective label claim and they indicated 
the non-interference of formulation excipients in the estimation. 
Therefore the proposed study results confirm that the developed 
method is a suitable technique for simultaneous estimation of 
ubidecarenone and vitamin E acetate in the combined dosage form.  
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